Jump to main content
Jump to site search
SCHEDULED MAINTENANCE Close the message box

Maintenance work is planned for Monday 16 August 2021 from 07:00 to 23:59 (BST).

Website performance may be temporarily affected and you may not be able to access some PDFs or images. If this does happen, refreshing your web browser should resolve the issue. We apologise for any inconvenience this might cause and thank you for your patience.


All chapters

CHAPTER 12

Prodrugs in the Treatment of Viral Diseases

Prodrug strategies have played a prominent role in the development of drugs to treat viral diseases. Implementation of prodrug approaches has been shown to improve the drug characteristics of agents to treat a wide range of viral diseases, including HIV, HBV, HCV, CMV, VZV, EBV, HSV and influenza. Prodrugs of antiviral agents have been used to address issues such as poor intestinal absorption because of the lack of membrane permeability or poor solubility. Prodrugs have also been used to enable tissue targeting. This chapter addresses the issues and challenges associated with prodrug design and development and highlights a number of case studies where prodrugs of antiviral agents have been used to solve pharmacokinetic or pharmaceutics problems that limited the development of the parent drug.

Publication details


Print publication date
10 Jun 2013
Copyright year
2013
Print ISBN
978-1-84973-657-2
PDF eISBN
978-1-84973-781-4
From the book series:
Drug Discovery